Hello!

BioBeers has listened to all of your comments, criticisms & requests, and is excited to respond to the “wisdom of the crowd” by introducing a new and expanded format that is guaranteed to please (we hope…)! Be certain to keep the feedback coming!

We have now tripled the fun by featuring three-events-in-one:

Part I CO BioInnovator Roundtables:

Literal roundtables (okay, at times they may be square or rectangular) guided by CO BioInnovators leading informal and interactive discussions about new products, ideas, technologies, diseases, regulatory topics, companies, etc. Expect several CO BioInnovator Roundtables per event that are open for 60 min. Stop by a single table or make the rounds and participate in all of the diverse conversations, eavesdrop or actively engage in the dialogue, the choice is yours all the while enjoying refreshments and light snacks! See the schedule below for the exciting line-up for CO BioInnovator Roundtables. Got something to say and interested in hosting your own Roundtable at the 4Q10 event…please let us know!

Part II CO New Biotech Meetup:

Following CO BioInnovator Roundtables the party moves from the lobby to the adjacent auditorium for the formal “Meetup” portion of the program where 5 minute presentations followed by 10 minutes of Q&A are presented by life science leaders highlighting important lessons learned, novel technologies and emerging companies, etc. Expect 3 to 4 presenters to last approximately 60 min. See the schedule below for the exciting line-up for the CO New Biotech Meetup. Interested in presenting at the 4Q10 CO New Biotech Meetup…please let us know!

Part III CO BioBeers:

And finally, let us not forget the old standby, CO BioBeers. Following The Colorado New Biotech Meetup adjourn back to the lobby for unbridled networking, elbow-rubbing, meeting and greeting; and have a beer on the house courtesy of our friends at Twisted Pine Brewerey while Catching-up with old friends and colleagues and making new connections too. We guarantee that between the content presented at the BioInnovator Roundtables and New Biotech Meetup there will be plenty to talk about at BioBeers.

SCHEDULE:

6:00 - 7:00 CO BioInnovator Roundtables

Table 1 | Nanotechnology-Driven Cancer Therapeutics - Bioinnovator Roundtable host: Len Pagliaro, PhD

Table 2 | Trends in Infection Control & Hospital Acquired Infections - Bioinnovator Roundtable host: Scott Gaisford

Table 3 | Healthcare Social Networking 2.0 - Bioinnovator Roundtable host: David Maizenberg

Table 4 | Emerging Biomedical Catheter Technologies -Bioinnovator Roundtable hosts: Walter Wong and Derek Kidd

Table 5 | Regulatory Strategies for Today and for the Future - Bioinnovator Roundtable host: Brenda Fielding

Table 6 | Future Bedside Cardiopulmonary Diagnostic Techniques - Bioinnovator Roundtable host: Tom Carpenter

Table 7 | New commercialization and proof of concept pathways for bioscience - Bioinnovator Roundtable host: Rick Silva, PhD

7:00 - 8:00 CO New Biotech Meetup: Welcome & Announcements 


Presentation 1 | Creating and Executing on Pivotal Clinical Trials (Michael Gerber, MD)

Presentation 2 | Innovating in the Age of Personalized Medicine (Rhonda Wallen)

Presentation 3 | Licensing and Commercializing out of the University and into the Marketplace: The Story of Barofold (Matt Seefeldt, PhD)

Presentation 4 | Building Successful Biotech Companies: The Stories of NeXstar, Pharmion & Clovis Oncology (Pat Mahaffy)

8:00 - 9:30 CO BioBeers

WHERE:

ATLAS Building (University Colorado, Boulder). Parking is available one-half block away at the University Memorial Center Parking lot (map to ATLAS and parking is HERE)

Please note that doors will be closed for the start of the CO New Biotech Meetup promptly at 7:00pm.

center]Be certain to RSVP ASAP at http://www.BioBeers.c... Please help us grow our nurturing and supportive life science ecosystem by sharing this invitation with friends and colleagues! Many thanks for your interest and participation.

PRESENTER BIOS

Dr. Michael Gerber, MD has almost 2 decades of experience in strategic planning, clinical and nonclinical drug development, global regulatory affairs, and product registration of innovative new chemical entities and biologics. He has helped develop 5 small molecule therapeutics and one recombinant protein. He has been a senior regulatory officer for FDA and EMEA drug development interactions and negotiations, dealing with multiple FDA Divisions: Cardiovascular and Renal, Pulmonary, Anesthesia Critical Care, Oncology, and Blood Products. He has participated in two IPOs: Allos Therapeutics in 2000 and Myogen Inc. in 2003, and has participated in raising more than $600M in private and public equity offerings with Gilead Sciences acquiring Myogen in 2006 for $2.5 billon.

Ms. Rhonda Wallen currently leads strategic marketing and special projects at Biodesix where she previously served as a consultant. In her consulting role at Cygnet Venture Management, she also served as interim management for senior level business development and marketing functions, typically working with life science company CEOs and founders to set the strategic direction of start-up companies, complete business plans and position the companies for financing. Ms. Wallen was formerly an investment professional with Sequel Venture Partners and has over 18 years of experience in the life science industry including venture investing, early stage company operations and corporate management. Prior to entering venture capital, Ms. Wallen held management roles at Bayer Pharmaceuticals and Guidant (now Boston Scientific) where she managed product planning and corporate development functions including the negotiation of numerous licensing and strategic transactions. She holds a BS in Biological Sciences from Stanford University and an MS and MBA from the University of Rochester School of Medicine and Dentistry and the Simon Graduate School of Business, respectively.

Matt Seefeldt, Ph.D., is VP of Research at Barofold. BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for bio-pharmaceutical companies, research institutions, and government agencies. PreEMT employs high pressure to disaggregate and refold proteins, which may have a significant impact on the quality of these biotherapeutics by improving their activity, homogeneity and safety. BaroFold also helps companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics and enable life-cycle management of protein therapeutics.

Mr. Pat Mahaffy is a founder of Clovis Oncology and has served as the President and Chief Executive Officer and a member of the board of directors since its inception. Previously, Mr. Mahaffy served in the same role at Pharmion, which he founded in 2000 and sold to Celgene in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen and its successor, NeXstar Pharmaceuticals. Prior to that, Mr. Mahaffy was a Vice President at Warburg Pincus. Mr. Mahaffy also serves on the boards of directors of Orexigen Therapeutics and Flexion Therapeutics. He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.